National Institute of Oncology, Budapest Report issue

Government Phase 2

Organization Overview

First Clinical Trial
2010
NCT01161368
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Alternative names

National Institute of Oncology Rath Gyorgy u. 7-9. 1122 Budapest

Active Ingredients

Drugs in Phase 2 Trials (2)

lapatinib (tykerb) (1 trial)

vinorelbine (navelbine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2